Minerva Adds New Board Member
This article was originally published in Scrip
Minerva Neurosciences, Inc., a company focused on therapies for the central nervous system, has appointed Dr. David J. Kupfer to its board of directors – effective immediately. Kupfer has authored more than 1,100 books, articles and book chapters and also chaired the American Psychiatric Association Task Force for the development of the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). He is a professor of psychiatry at the University of Pittsburgh School of Medicine, where he also chaired that department for 26 years. Kupfer is the founding president of the International Society of Bipolar Disorders and was elected to the National Academy of Medicine (formerly the Institute of Medicine) in 1990.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.